Airway Clearance Devices Market Analysis

Airway Clearance Devices Market Analysis

Based on device type, the airway clearance devices market is segmented as oscillatory positive expiratory pressure (O-PEP), high frequency chest wall oscillation (HFCWO), intrapulmonary percussive ventilation (IPV), and others. High frequency chest wall oscillation (HFCWO) segment accounted for USD 183.7 million in 2022 and is expected to reach USD 313.2 million by 2032. This considerable revenue share is attributable to the multiple benefits related to the use of HFCWO in airway clearance therapies. This technique employs the use of a mechanical devices to apply rapid oscillations or vibrations to the chest wall, helping to loosen & mobilize mucus, making it easier to clear from the airway. This can lead to improved lung function and reduced risk of respiratory infections. These devices commonly allow customizable settings, such as adjusting the frequency and intensity of oscillations. This enables healthcare providers to modify the treatment to the specific needs of each patient. HFCWO sessions can provide a consistent and standardized treatment approach compared to some other airway clearance techniques.
 

Based on application, the airway clearance devices market is segmented as chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis, neuromuscular, and others. The cystic fibrosis segment accounted for the considerable revenue share in 2022 and is expected to propel at a 5.4% CAGR from 2023-2032. This market share is due to the high prevalence & incidence rates associated with this condition. The increasing prevalence of cystic fibrosis is a major growth driver for the market. Cystic fibrosis (CF) has traditionally been defined as the most common life-threatening inherited disorder. According to the Cystic Fibrosis Foundation, in 2020, an estimated 70,000 people worldwide are living with cystic fibrosis. Additionally, advancements in medical care and increased life expectancy have contributed to a growing adult cystic fibrosis population. This expansion in the patient pool underscores the need for effective airway clearance devices.
 

Based on end-use, the airway clearance devices market is segmented as hospitals, homecare settings, and others. The homecare settings segment accounted for majority revenue share and was valued at over USD 377 million in 2022. This significant segment growth is majorly attributed to the surging patient preference for the use of airway clearance devices in homecare settings. The trend towards providing respiratory care in home settings has gained momentum, driven by factors such as patient convenience, cost-effectiveness, and the desire to reduce hospital readmissions.
 

Airway clearance devices that are portable, user-friendly, and suitable for home use have experienced a surge in demand. The ability for patients to self-manage their respiratory conditions with proper training and guidance further contributes to market growth. Also, the development of easy to use & convenient airway clearance devices is further set to drive its adoption in the homecare settings that is anticipated to boost the market size.
 

The U.S. airway clearance devices market is predicted to reach over USD 288 million by 2032. This dominant market growth is primarily owing to several variables including the high disease burden of respiratory conditions, rise in awareness regarding airway clearance devices, and supportive legislative policies in the country. For instance, as per the American Lung Association, in 2018, approximately 9 million adults, or 3.6% of individuals aged 18 or above were suffering from chronic bronchitis in the U.S. Similarly, around 2 million adults were suffering from emphysema. These statistics indicate substantial market expansion opportunity for key players operating in this industry. Moreover, facilitative healthcare policies and reimbursement frameworks that support the use of airway clearance devices in cystic fibrosis management also contribute to market progress.